newsfilter
← Latest News
GlobeNewswire·

ArriVent BioPharma Reports Full Year 2023 Financial Results

Company progresses the development of furmonertinib with a data readout planned for 2024Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201 million initial